DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography

Journal Article · · Nature Communications
ORCiD logo [1];  [2];  [3];  [2];  [1];  [2]; ORCiD logo [4];  [5];  [6]; ORCiD logo [6]; ORCiD logo [7];  [6];  [6];  [6];  [8];  [1];  [1];  [9]; ORCiD logo [6]; ORCiD logo [2] more »; ORCiD logo [1] « less
  1. Elasmogen Ltd., Aberdeen (United Kingdom)
  2. Univ. of Wisconsin, Madison, WI (United States). School of Medicine and Public Health
  3. Univ. of Wisconsin, Madison, WI (United States). School of Medicine and Public Health; Medical School of Wisconsin, Milwaukee, WI (United States)
  4. Medical School of Wisconsin, Milwaukee, WI (United States)
  5. Univ. of Minnesota Medical School, Minneapolis, MN (United States); Univ. of Minnesota, Minneapolis, MN (United States)
  6. Univ. of Minnesota, Minneapolis, MN (United States)
  7. Univ. of Minnesota Medical School, Minneapolis, MN (United States)
  8. Cornell Univ., Lemont, IL (United States). Advanced Photon Source (APS)
  9. Elasmogen Ltd., Aberdeen (United Kingdom); Univ. of Aberdeen (United Kingdom)

Single-domain Variable New Antigen Receptors (VNARs) from the immune system of sharks are the smallest naturally occurring binding domains found in nature. Possessing flexible paratopes that can recognize protein motifs inaccessible to classical antibodies, VNARs have yet to be exploited for the development of SARS-CoV-2 therapeutics. Here, we detail the identification of a series of VNARs from a VNAR phage display library screened against the SARS-CoV-2 receptor binding domain (RBD). The ability of the VNARs to neutralize pseudotype and authentic live SARS-CoV-2 virus rivalled or exceeded that of full-length immunoglobulins and other single-domain antibodies. Crystallographic analysis of two VNARs found that they recognized separate epitopes on the RBD and had distinctly different mechanisms of virus neutralization unique to VNARs. Structural and biochemical data suggest that VNARs would be effective therapeutic agents against emerging SARS-CoV-2 mutants, including the Delta variant, and coronaviruses across multiple phylogenetic lineages. This study highlights the utility of VNARs as effective therapeutics against coronaviruses and may serve as a critical milestone for nearing a paradigm shift of the greater biologic landscape.

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States)
Sponsoring Organization:
NIH; USDOE Office of Science (SC)
OSTI ID:
1841247
Journal Information:
Nature Communications, Journal Name: Nature Communications Journal Issue: 1 Vol. 12; ISSN 2041-1723
Publisher:
Nature Publishing GroupCopyright Statement
Country of Publication:
United States
Language:
ENGLISH

References (35)

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients journal May 2021
Vpr Is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes journal February 1995
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells journal July 2020
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies journal June 2020
COVID-19-neutralizing antibodies predict disease severity and survival journal January 2021
An Infectious cDNA Clone of SARS-CoV-2 journal May 2020
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies journal March 2021
Maturation of Shark Single-domain (IgNAR) Antibodies: Evidence for Induced-fit Binding journal March 2007
Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression journal September 2005
A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks journal March 1995
Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 journal July 2013
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor journal October 2013
Origin and evolution of pathogenic coronaviruses journal December 2018
Structural basis of receptor recognition by SARS-CoV-2 journal March 2020
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike journal July 2020
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies journal October 2020
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 journal March 2021
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient journal July 2020
Next-generation flexible formats of VNAR domains expand the drug platform's utility and developability journal October 2018
Neutralizing Activity of BNT162b2-Elicited Serum journal April 2021
Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees journal May 2021
Phaser crystallographic software journal July 2007
XDS journal January 2010
PHENIX: a comprehensive Python-based system for macromolecular structure solution journal January 2010
Features and development of Coot journal March 2010
SARS‐CoV‐2 neutralization and serology testing of COVID‐19 convalescent plasma from donors with nonsevere disease journal October 2020
Crystal Structure of a Shark Single-Domain Antibody V Region in Complex with Lysozyme journal September 2004
Relief and worry for immune-suppressed people journal April 2021
A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV journal April 2020
Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients journal June 2021
Essential requirement for JPT2 in NAADP-evoked Ca 2+ signaling journal March 2021
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity journal November 1995
Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development journal December 2017
An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model journal March 2019
The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates journal August 2021